Sun Pharmaceutical Industries Limited has announced the presentation of 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27-31, 2026 in Denver, Colorado. The comprehensive data presentations underscore the company's expertise across dermatology and immunology, reinforcing its commitment to advancing patient care in psoriasis, alopecia areata, and acne.

Research Portfolio Overview

The pharmaceutical company's extensive research presentation spans three key therapeutic areas with notable clinical developments:

Key Clinical Developments

ILUMYA Research Advances

The company presented significant data for ILUMYA, including a Phase 3b study demonstrating sustained efficacy and safety over 52 weeks in moderate-to-severe psoriasis affecting the nails. Real-world evidence from the PPD™ CorEvitas™ Psoriasis Registry showed that ILUMYA delivers holistic disease management, achieving sustained disease control across diverse patient populations worldwide.

LEQSELVI Breakthrough Results

Pooled data from the pivotal THRIVE-AA1 and THRIVE-AA2 trials revealed that LEQSELVI demonstrated significant scalp hair regrowth as early as Week 8 and Week 12, with continuous improvements over time. A landmark survey highlighted meaningful gaps in perceptions of disease burden and treatment goals between patients and clinicians, emphasizing the need for better patient-centered care alignment.

WINLEVI Combination Therapy Progress

An open-label, 52-week study of WINLEVI showed significant and progressive reduction in casual facial sebum production and acne severity, reinforcing its ability to directly target the androgen-sebum pathway. Pilot combination therapies demonstrated that WINLEVI may provide benefit in multimodal acne treatments, signaling broader clinical applicability.

Strategic Research Impact

According to Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer at Sun Pharma, "The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice."

The company also offered hands-on, immersive engagement opportunities at booth #2915, providing clinicians with interactive experiences highlighting the full dermatology and immunology portfolio.

Source: None/Company/INE044A01036/0b7a4192-f736-4195-9a90-82a507888e46.pdf

Sun pharmaceutical Industries Ltd. executed a substantial block trade on the National Stock Exchange (NSE), marking significant trading activity in the pharmaceutical sector. The transaction represents a notable institutional movement in one of India's leading pharmaceutical companies.

Transaction Details

The block trade demonstrated considerable market activity with specific parameters that highlight the scale of the transaction:

Market Implications

Block trades typically involve large institutional investors and are executed outside the regular market to avoid impacting the stock price significantly. These transactions often indicate:

• Institutional portfolio rebalancing
• Large-scale investment decisions by mutual funds or foreign institutional investors
• Strategic stake changes by major shareholders

The execution at Rs. 1800.00 per share reflects the current market valuation and investor confidence in the pharmaceutical sector. Such substantial transactions provide insights into institutional sentiment towards Sun Pharmaceutical Industries and the broader pharmaceutical industry.

About Block Trading

Block trades are large-volume transactions that are typically negotiated privately between parties and then reported to the exchange. These trades help maintain market stability by preventing large orders from causing significant price volatility during regular trading hours.